Clinical Trials Logo

Clinical Trial Summary

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.


Clinical Trial Description

Eligible patients will be those patients with newly diagnosed, histologically confirmed advanced (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] Stage III-IV) ovarian, primary peritoneal cancer and/or fallopian-tube cancer. All patients should be candidates for cytoreductive surgery which could be conducted as immediate upfront primary surgery following diagnosis or can be conducted after initiation of platinum based neoadjuvant chemotherapy. All patients should be eligible to start first line platinum based chemotherapy in combination with bevacizumab. The study aims to evaluate the efficacy and safety of standard of care (SoC) platinum-based chemotherapy and bevacizumab followed by maintenance bevacizumab either as monotherapy, or in combination with durvalumab, or in combination with durvalumab and olaparib. Therefore, this study aims to see which combination allows patients to live longer without the cancer coming back or getting worse. The study is also looking to see which combination makes patients live longer and how the treatment and the cancer affects their quality of life. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03737643
Study type Interventional
Source AstraZeneca
Contact
Status Active, not recruiting
Phase Phase 3
Start date January 4, 2019
Completion date May 25, 2028

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03611179 - Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer Phase 2
Not yet recruiting NCT06055348 - SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer Phase 1/Phase 2
Completed NCT04135521 - Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
Completed NCT01462149 - Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer Phase 2
Terminated NCT03292172 - A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Phase 1
Not yet recruiting NCT05794659 - Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer Phase 2
Completed NCT04360629 - Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer N/A
Completed NCT00516724 - Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel Phase 1
Completed NCT03158935 - The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial Phase 1
Completed NCT05775549 - A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
Completed NCT01290471 - Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors Phase 1
Recruiting NCT04862325 - SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS N/A
Completed NCT01989546 - Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Phase 1/Phase 2
Recruiting NCT04556539 - Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer Phase 2
Completed NCT03161132 - Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin Phase 2
Active, not recruiting NCT04065009 - The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer Phase 3
Active, not recruiting NCT01844986 - Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. Phase 3
Not yet recruiting NCT05924776 - Plasmodium Immunotherapy for Advanced Ovarian Cancer Phase 2/Phase 3
Active, not recruiting NCT03878849 - Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® Phase 2